PKR ACTIVATION VIA HYBRIDIZATION CHAIN REACTION
    1.
    发明申请
    PKR ACTIVATION VIA HYBRIDIZATION CHAIN REACTION 审中-公开
    PKR激活通过混合链反应

    公开(公告)号:WO2007044727A2

    公开(公告)日:2007-04-19

    申请号:PCT/US2006039571

    申请日:2006-10-06

    CPC classification number: C12Q1/6813 C12Q2525/301

    Abstract: The present application relates to the use of hybridization chain reaction (HCR) to form double stranded RNA polymers in the presence of a target, such as a nucleic acid associated with a disease or disorder. The RNA polymers are preferably able to activate the RNA-dependent kinase PKR. Activation of PKR via RNA-HCR can be used to treat a wide variety of diseases and disorders by specifically targeting diseased cells.

    Abstract translation: 本申请涉及杂交链反应(HCR)在靶(例如与疾病或病症相关的核酸)存在下形成双链RNA聚合物的用途。 RNA聚合物优选能够激活RNA依赖性激酶PKR。 通过RNA-HCR激活PKR可用于通过特异性靶向患病细胞来治疗多种疾病和病症。

    6.
    发明专利
    未知

    公开(公告)号:AT480550T

    公开(公告)日:2010-09-15

    申请号:AT05730392

    申请日:2005-03-22

    Abstract: The present invention relates to the use of nucleic acid probes to identify analytes in a sample. In the preferred embodiments, metastable nucleic acid monomers are provided that associate in the presence of an initiator nucleic acid. Upon exposure to the initiator, the monomers self-assemble in a hybridization chain reaction. The initiator nucleic acid may be, for example, a portion of an analyte to be detected or may be part of an initiation trigger such that it is made available in the presence of a target analyte.

    7.
    发明专利
    未知

    公开(公告)号:AT526975T

    公开(公告)日:2011-10-15

    申请号:AT06836249

    申请日:2006-10-06

    Abstract: The present application relates to the use of hybridization chain reaction (HCR) to form double stranded RNA polymers in the presence of a target, such as a nucleic acid associated with a disease or disorder. The RNA polymers are preferably able to activate the RNA-dependent kinase PKR. Activation of PKR via RNA-HCR can be used to treat a wide variety of diseases and disorders by specifically targeting diseased cells.

Patent Agency Ranking